Can sequences turn a profit?

The public release of the draft mouse genome sequence reopens the debate on the commercial viability of genome sequencing.

| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

MARYLAND — Michael C. Nehls calls it "a breakthrough that is already changing how we will elucidate novel biology in order to advance medicine." He is just one among thousands of biomedical researchers who expect to profit from the public release of the draft mouse genome sequence last week.

In Nehls's case, the profit could be financial as well as intellectual. He is CEO of Ingenium Pharmaceuticals AG, a Munich company that seeks to identify gene function by screening randomly mutated mice for abnormalities relevant to human disorders and then identifying which genes are involved and what they do. It took eight Ingenium researchers four years to clone the mutation that causes the so-called nude phenotype. The nude mouse is a critical model for biomedical research because it lacks a mature immune system. In combination with technologies such as analysis of single nucleotide polymorphisms (SNPs), the availability of the mouse ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Tabitha Powledge

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide